AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,703 · see citing works

Oncogenically active MYD88 mutations in human lymphoma

Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,514 · see citing works

IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples

Varghese, F., Bukhari, A. B., Malhotra, R., & De, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096801 · Cited by 1,318 · see citing works

Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome

Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pasic, S., Stojković, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 987 · see citing works

Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein

Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · see citing works

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 921 · see citing works

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897 · see citing works

Oncogene Addiction

Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805 · see citing works

SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity

Yoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P. E., Groopman, J. D., Manning, J. E., Harris, C. C., & Herman, J. G. (2001) · Nature Genetics · doi:10.1038/ng0501-29 · Cited by 724 · see citing works

Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation

Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716 · see citing works

Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes

Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658 · see citing works

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Buller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A. E. M., Verhamme, P. B., & Weitz, J. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 637 · see citing works

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice

Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A. E., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 616 · see citing works

Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II

Taylor, C. R., & Levenson, R. M. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02513.x · Cited by 613 · see citing works

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells

Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555 · see citing works

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A. M., Buettner, R., Proia, D. A., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526 · see citing works

Targeting nuclear RNA for in vivo correction of myotonic dystrophy

Wheeler, T. M., Leger, A. J., Pandey, S., MacLeod, A. R., Nakamori, M., Cheng, S. H., Wentworth, B. M., Bennett, C. F., & Thornton, C. A. (2012) · Nature · doi:10.1038/nature11362 · Cited by 503 · see citing works

Targeting APOC3 in the familial chylomicronemia syndrome

Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491 · see citing works

Nonviral delivery of synthetic siRNAs in vivo

Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464 · see citing works

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

Monia, B. P., Johnston, J. F., Geiger, T. M., Muller, M., & Fabbro, D. (1996) · Nature Medicine · doi:10.1038/nm0696-668 · Cited by 447 · see citing works

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamò, A., Raz, R., Karras, J. G., Levy, D. E., & Inghirami, G. (2005) · Nature Medicine · doi:10.1038/nm1249 · Cited by 441 · see citing works

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

Zamò, A., Chiarle, R., Piva, R., Howes, J. E., Fan, Y., Chilosi, M., Levy, D. E., & Inghirami, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205152 · Cited by 397 · see citing works

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

Stein, C. A., Hansen, J. B., Lai, J. C. H., Wu, S., Voskresenskiy, A. M., H⊘g, A., Worm, J., Hedtjärn, M., Souleimanian, N. E., Miller, P. S., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp841 · Cited by 384 · see citing works

Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane

Zuckerman, J. E., Choi, C. H. J., Han, H., & Davis, M. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200718109 · Cited by 375 · see citing works

2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells

Baker, B. F., Lot, S. S., Condon, T. P., Cheng-Flournoy, S., Lesnik, E. A., Sasmor, H. M., & Bennett, C. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11994 · Cited by 374 · see citing works

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., Saunders, L. M., Mullally, A., Abdel-Wahab, O. I., et al. (2012) · Nature · doi:10.1038/nature11303 · Cited by 370 · see citing works

First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313 · see citing works

Translating insights from the cancer genome into clinical practice

Chin, L., & Gray, J. W. (2008) · Nature · doi:10.1038/nature06914 · Cited by 299 · see citing works

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

Koller, E., Vincent, T. M., Chappell, A. E., De, S., Manoharan, M., & Bennett, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr089 · Cited by 284 · see citing works

Short Antisense Oligonucleotides with Novel 2′−4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals

Seth, P. P., Siwkowski, A. M., Allerson, C. R., Vasquez, G., Lee, S. S., Prakash, T. P., Wancewicz, E. V., Witchell, D. R., & Swayze, E. E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801294h · Cited by 266 · see citing works

Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils

Torti, D., & Trusolino, L. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100176 · Cited by 248 · see citing works

Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship

Kim, H., Huang, W., Jiang, X., Pennicooke, B. H., Park, P. J., & Johnson, M. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909896107 · Cited by 239 · see citing works

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Hotte, S. J., Yu, E. Y., Tu, D., Eigl, B. J., Tannock, I. F., Fred Saad, C., North, S. A., Powers, J., Gleave, M. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8771 · Cited by 235 · see citing works

Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression

Brantley, E. C., Nabors, B., Gillespie, G. Y., Choi, Y., Palmer, C. A., Harrison, K., Roarty, K. P., & Benveniste, E. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0618 · Cited by 191 · see citing works

STAT inhibitors for cancer therapy

Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-90 · Cited by 191 · see citing works

JAK1 Activates STAT3 Activity in Non-Small–Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling

Song, L., Rawal, B., Nemeth, J. A., & Haura, E. B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0502 · Cited by 178 · see citing works

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Wong, A. L. A., Soo, R. A., Tan, D. S. W., Lee, S. C., Lim, J. S. J., Marban, P., Kong, L. R., Lee, Y. J., Wang, L. Z., Thuya, W. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv026 · Cited by 175 · see citing works

Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma

Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M., & Kurzrock, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.575 · Cited by 164 · see citing works

Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS

Østergaard, M. E., Southwell, A. L., Kordasiewicz, H. B., Watt, A. T., Skotte, N. H., Doty, C. N., Vaid, K., Villanueva, E. B., Swayze, E. E., Bennett, C. F., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt725 · Cited by 163 · see citing works

Rac1 mediates STAT3 activation by autocrine IL-6

Faruqi, T. R., Gomez, D., Bustelo, X. R., Bar‐Sagi, D., & Reich, N. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161281298 · Cited by 147 · see citing works

Quantitation of Phosphorothioate Oligonucleotides in Human Plasma

Leeds, J. M., Graham, M. J., Truong, L., & Cummins, L. L. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0088 · Cited by 143 · see citing works

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

Hong, D. S., Kurzrock, R., Oh, Y. W., Wheler, J. J., Naing, A., Brail, L. H., Callies, S., André, V., KADAM, S. K., Nasir, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0430 · Cited by 140 · see citing works

Mouse hematopoietic cell–targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging–like phenotype

Mantel, C., Messina‐Graham, S., Moh, A., Cooper, S. H., Hangoc, G., Fu, X.-Y., & Broxmeyer, H. E. (2012) · Blood · doi:10.1182/blood-2012-01-404004 · Cited by 136 · see citing works

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

Fred Saad, C., Hotte, S. J., North, S. A., Eigl, B. J., Chi, K., Czaykowski, P., Wood, L. A., Pollak, M., Berry, S. R., Lattouf, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0859 · Cited by 132 · see citing works

Imatinib and beyond—exploring the full potential of targeted therapy for CML

Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.112 · Cited by 120 · see citing works

STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma

Looyenga, B. D., Hutchings, D., Cherni, I., Kingsley, C., Weiss, G. J., & MacKeigan, J. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030820 · Cited by 120 · see citing works

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2480-2 · Cited by 115 · see citing works

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma

Scuto, A., Kujawski, M., Kowolik, C. M., Krymskaya, L., Wang, L., Weiss, L. M., DiGiusto, D. L., Yu, H., Forman, S. J., & Jove, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2380 · Cited by 114 · see citing works

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Talbot, D. C., Ranson, M., Davies, J., Lahn, M., Callies, S., André, V., KADAM, S. K., Burgess, M., Slapak, C. A., Olsen, A. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1932 · Cited by 100 · see citing works

TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues—a comparative study of oligonucleotide length, design and chemistry

Murray, S., Ittig, D., Koller, E., Berdeja, A., Chappell, A. E., Prakash, T. P., Norrbom, M., Swayze, E. E., Leumann, C. J., & Seth, P. P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks273 · Cited by 91 · see citing works

A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer

Villalona-Calero, M. A., Ritch, P. S., Figueroa, J. A., Otterson, G. A., Belt, R. J., Dow, E., George, S., Leonardo, J. M., McCachren, S., Miller, G. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0779 · Cited by 87 · see citing works

Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys

Burel, S. A., Han, S.-R., Lee, H.-S., Norris, D. A., Lee, B., Machemer, T., Park, S., Zhou, T., He, G., Kim, Y., et al. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0422 · Cited by 77 · see citing works

A functional role of Stat3 in in vivo megakaryopoiesis

Kirito, K., Osawa, M., Morita, H., Shimizu, R., Yamamoto, M. P., Oda, A., Fujita, H., Tanaka, M., Nakajima, K., Miura, Y., et al. (2002) · Blood · doi:10.1182/blood.v99.9.3220 · Cited by 68 · see citing works

Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines

DeArmond, D. T., Brattain, M. G., Jessup, J. M., Kreisberg, J. I., Malik, S. N., Zhao, S., & Freeman, J. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206966 · Cited by 66 · see citing works

Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications

Yu, R. Z., Grundy, J. S., Henry, S. P., Kim, T., Norris, D. A., Burkey, J., Wang, Y., Vick, A., & Geary, R. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.69 · Cited by 50 · see citing works

Systemic Administration of a Cyclic Signal Transducer and Activator of Transcription 3 (STAT3) Decoy Oligonucleotide Inhibits Tumor Growth without Inducing Toxicological Effects

Sen, M., Paul, K. C., Freilino, M. L., Li, H., Li, C., Johnson, D. E., Wang, L., Eiseman, J. L., & Grandis, J. R. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00104 · Cited by 38 · see citing works

Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors

Zhang, M., Yao, Z., Zhang, Z., Garmestani, K., Goldman, C. K., Ravetch, J. V., Janik, J. E., Brechbiel, M. W., & Waldmann, T. A. (2006) · Blood · doi:10.1182/blood-2005-11-4607 · Cited by 35 · see citing works

Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model

Murakami, T., Takigawa, N., Ninomiya, T., Ochi, N., Yasugi, M., Honda, Y., Kubo, T., Ichihara, E., Hotta, K., Tanimoto, M., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.011 · Cited by 34 · see citing works

Prognostic Value of Circulating Cytokines on Overall Survival and Disease-Free Survival in Cancer Patients

Visconti, L. M., Nelissen, K., Deckx, L., van den Akker, M., Adriaensen, W. J., Daniëls, L., Matheï, C., Linsen, L., Hellings, N., Stinissen, P., et al. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.13.122 · Cited by 26 · see citing works

Integrated Bioinformatics Analysis for Cancer Target Identification

Yang, Y., Adelstein, S. J., & Kassis, A. I. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-027-0_25 · Cited by 6 · see citing works

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110 · see citing works

Long Noncoding RNAs in Cancer Pathways

Schmitt, A. M., & Chang, H. Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.010 · Cited by 2,991 · see citing works

Targeting apoptosis in cancer therapy

Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,594 · see citing works

Advances in oligonucleotide drug delivery

Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,026 · see citing works

Tumor microenvironment as a therapeutic target in cancer

Xiao, Y. Q., & Yu, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,977 · see citing works

Turning foes to friends: targeting cancer-associated fibroblasts

Chen, X., & Song, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,884 · see citing works

The role of non-coding RNAs in oncology

Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619 · see citing works

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102 · see citing works

Targeting STAT3 in Cancer Immunotherapy

Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,075 · see citing works

RNA-Targeted Therapeutics

Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841 · see citing works

Antisense technology: an overview and prospectus

Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775 · see citing works

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652 · see citing works

Long noncoding RNAs in cancer metastasis

Liu, S. J., Dang, H. X., Lim, D. A., Feng, F. Y.-C., & Maher, C. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00353-1 · Cited by 645 · see citing works

Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

Shen, X., & Corey, D. R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 639 · see citing works

Therapeutic Targeting of Long Non-Coding RNAs in Cancer

Arun, G., Diermeier, S. D., & Spector, D. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.001 · Cited by 612 · see citing works

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 535 · see citing works

Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map

Huynh, J., Chand, A. L., Gough, D. J., & Ernst, M. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 507 · see citing works

Long Noncoding RNA in Cancer: Wiring Signaling Circuitry

Lin, C., & Yang, L. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.008 · Cited by 488 · see citing works

Emerging roles of lncRNA in cancer and therapeutic opportunities.

Jiang, M., Ni, J., Cui, W., Wang, B., & Zhuo, W. (2019) · PubMed Central · Cited by 476 · see citing works

Targeting cytokine and chemokine signaling pathways for cancer therapy

Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 491 · see citing works

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 468 · see citing works

The Medicinal Chemistry of Therapeutic Oligonucleotides

Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 435 · see citing works

Pharmacology of Antisense Drugs

Bennett, C. F., Baker, B. F., Pham, N. C., Swayze, E. E., & Geary, R. S. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 429 · see citing works

STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review

Qin, J., Li, Y., Zhang, J., & Zhang, W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 407 · see citing works

Alternative‐splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics

Urbanski, L. M., Leclair, N. K., & Anczuków, O. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1476 · Cited by 381 · see citing works

New Modalities for Challenging Targets in Drug Discovery

Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382 · see citing works

“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway

Bousoik, E., & Aliabadi, H. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00287 · Cited by 388 · see citing works

Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets

Klingenberg, M., Matsuda, A., Diederichs, S., & Patel, T. C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.009 · Cited by 354 · see citing works

Antisense technology: A review

Crooke, S. T., Liang, X., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 333 · see citing works

STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis

Heichler, C., Koop, K., Schmied, A., Geppert, C. I., Schmid, B., Wirtz, S. J., Thoma, O., Kramer, V., Waldner, M. J., Büttner, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319200 · Cited by 330 · see citing works

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution

Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314 · see citing works

Recent progress in non-native nucleic acid modifications

McKenzie, L. K., El-Khoury, R., Thorpe, J. D., Damha, M. J., & Hollenstein, M. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01430c · Cited by 300 · see citing works

The powerful world of antisense oligonucleotides: From bench to bedside

Quéméner, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1594 · Cited by 279 · see citing works

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Hu, Y., Dong, Z., & Liu, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02949-5 · Cited by 288 · see citing works

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Reilley, M. J., Mccoon, P. E., Cook, C., Lyne, P. D., Kurzrock, R., Kim, Y., Woessner, R. D., Younes, A., Nemunaitis, J. J., Fowler, N. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 268 · see citing works

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity

Kamerkar, S., Leng, C., Burenkova, O. V., Jang, S. C., McCoy, C., Zhang, K. X., Dooley, K., Kasera, S., Zi, T., Sisó, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj7002 · Cited by 264 · see citing works

Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies

Mhaidly, R., & Mechta‐Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 258 · see citing works

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

Tiacci, E., Ladewig, E., Schiavoni, G., Penson, A., Fortini, E., Pettirossi, V., Wang, Y., Rosseto, A. S., Venanzi, A., Vlasevska, S., et al. (2018) · Blood · doi:10.1182/blood-2017-11-814913 · Cited by 234 · see citing works

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01530 · Cited by 233 · see citing works

IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma

Xu, J., Lin, H., Wu, G., Zhu, M., & Li, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.760971 · Cited by 228 · see citing works

Do STAT3 inhibitors have potential in the future for cancer therapy?

Wong, A. L. A., Hirpara, J. L., Pervaiz, S., Eu, J. Q., Sethi, G., & Goh, B.-C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1351941 · Cited by 227 · see citing works

CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1

Lee, Y., Shin, J. H., Longmire, M. R., Wang, H., Kohrt, H. E. K., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 221 · see citing works

JAK-STAT signaling in cancer: From cytokines to non-coding genome

Pěnčík, J., Pham, H. T. T., Schmoellerl, J., Javaheri, T., Schlederer, M., Čulig, Z., Merkel, O., Moriggl, R., Grebien, F., & Kenner, L. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.017 · Cited by 217 · see citing works

LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription

Xiu, B., Chi, Y., Liu, L., Chi, W., Zhang, Q., Chen, J., Guo, R., Si, J., Li, L., Xue, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1115-y · Cited by 209 · see citing works

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies

Zhu, X., Chen, L., Liu, L., & Niu, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01044 · Cited by 205 · see citing works

Targeting and engineering long non-coding RNAs for cancer therapy

Coan, M., Haefliger, S., Ounzain, S., & Johnson, R. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00693-2 · Cited by 209 · see citing works

The JAK/STAT3 axis: A comprehensive drug target for solid malignancies

Huynh, J., Etemadi, N., Hollande, F., Ernst, M., & Büchert, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.001 · Cited by 197 · see citing works

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer

Park, S., Choi, J., & Nam, J. (2019) · Cancers · doi:10.3390/cancers11070965 · Cited by 190 · see citing works

Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes

Ricketts, T. D., Prieto‐Domínguez, N., Gowda, P. S., & Ubil, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642285 · Cited by 181 · see citing works

Aberrant RNA Splicing in Cancer and Drug Resistance

Wang, B., & Lee, N. (2018) · Cancers · doi:10.3390/cancers10110458 · Cited by 178 · see citing works

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177 · see citing works

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

Lu, C., Talukder, A. M., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 176 · see citing works

Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition

Cheng, J.-T., Wang, L., Wang, H., Tang, F.-R., Cai, W.-Q., Sethi, G., Xin, H.-W., & Ma, Z. (2019) · Cells · doi:10.3390/cells8101178 · Cited by 173 · see citing works

STAT3 pathway in cancers: Past, present, and future

Wang, H., Man, Q., Huo, F., Gao, X., Lin, H., Li, S.-R., Wang, J., Su, F., Cai, L., Shi, Y., et al. (2022) · MedComm · doi:10.1002/mco2.124 · Cited by 172 · see citing works

Targeting cancer‐related inflammation in the era of immunotherapy

Nakamura, K., & Smyth, M. J. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.126 · Cited by 163 · see citing works

Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs

Gadina, M., Johnson, C., Schwartz, D. M., Bonelli, M. M., Hasni, S., Kanno, Y., Changelian, P. S., Laurence, A. D. J., & O’Shea, J. J. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0218-084r · Cited by 160 · see citing works

STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer

Oweida, A. J., Darragh, L. B., Phan, A. V., Binder, D. C., Bhatia, S., Mueller, A. C., Court, B. V., Milner, D. C., Raben, D., Woessner, R. D., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz036 · Cited by 156 · see citing works

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

Barata, P. C., Sood, A. K., & Hong, D. S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.004 · Cited by 153 · see citing works

Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer

Gugnoni, M., & Ciarrocchi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081924 · Cited by 151 · see citing works

Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies

Li, Y.-R., Fang, Y., Lyu, Z., Zhu, Y., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04575-9 · Cited by 149 · see citing works

Clinical landscape of macrophage-reprogramming cancer immunotherapies

Rannikko, J. H., & Hollmén, M. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02715-6 · Cited by 153 · see citing works

Mitochondrial Stat3, the need for design thinking

Yang, R., & Rincon, M. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15153 · Cited by 147 · see citing works

YY1 regulates cancer cell immune resistance by modulating PD-L1 expression

Hays, E., & Bonavida, B. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.001 · Cited by 144 · see citing works

Image based detection and targeting of therapy resistance in pancreatic adenocarcinoma

Fox, R. G., Lytle, N. K., Jaquish, D., Park, F. D., Ito, T., Bajaj, J., Koechlein, C. S., Zimdahl, B., Yano, M., Kopp, J. L., et al. (2016) · Nature · doi:10.1038/nature17988 · Cited by 134 · see citing works

STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma

Lee, C., & Cheung, S. (2019) · Cancers · doi:10.3390/cancers11111646 · Cited by 142 · see citing works

Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer

Diamantopoulos, M. A., Tsiakanikas, P., & Scorilas, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.10 · Cited by 139 · see citing works

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies

Arora, L., Kumar, A. P., Arfuso, F., Chng, W. J., & Sethi, G. (2018) · Cancers · doi:10.3390/cancers10090327 · Cited by 124 · see citing works

The Interaction of Phosphorothioate-Containing RNA Targeted Drugs with Proteins Is a Critical Determinant of the Therapeutic Effects of These Agents

Crooke, S. T., Seth, P. P., Vickers, T. A., & Liang, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04928 · Cited by 127 · see citing works

STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity

Su, Y., Banerjee, S., White, S. V., & Kortylewski, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061803 · Cited by 123 · see citing works

Immune Checkpoint Inhibition in Head and Neck Cancer

Forster, M. D., & Devlin, M.-J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00310 · Cited by 121 · see citing works

Stem and progenitor cell alterations in myelodysplastic syndromes.

Shastri, A., Will, B., Steidl, U., & Verma, A. (2017) · Blood · doi:10.1182/blood-2016-10-696062 · Cited by 118 · see citing works

Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment

Piperi, C., Papavassiliou, K. A., & Papavassiliou, A. G. (2019) · Cells · doi:10.3390/cells8111398 · Cited by 119 · see citing works

Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11

Metcalfe, R. D., Putoczki, T. L., & Griffin, M. D. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01424 · Cited by 112 · see citing works

The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment

Chang, N., Ahn, S. H., Kong, D., Lee, H. W., & Nam, D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.004 · Cited by 112 · see citing works

Antisense oligonucleotides: absorption, distribution, metabolism, and excretion

Shadid, M., Badawi, M. A., & Abulrob, A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1992382 · Cited by 111 · see citing works

A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma

Zhou, Q.-Q., Tian, W., Jiang, Z., Huang, T.-T., Ge, C., Liu, T.-F., Zhao, F.-Y., Chen, T.-Y., Cui, Y., Li, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2480 · Cited by 70 · see citing works

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Kurt, F. G. Ö., Lasser, S., Arkhypov, I., Utikal, J. S., & Umansky, V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170762 · Cited by 109 · see citing works

STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects

Ashrafizadeh, M., Zarrabi, A., Orouei, S., Zarrin, V., Moghadam, E. R., Zabolian, A., Mohammadi, S., Hushmandi, K., Gharehaghajlou, Y., Makvandi, P., et al. (2020) · Biology · doi:10.3390/biology9060126 · Cited by 108 · see citing works

Targeting STAT3 in cancer and autoimmune diseases

Gharibi, T., Babaloo, Z., Hosseini, A., Abdollahpour‐Alitappeh, M., Hashemi, V., Marofi, F., Nejati‐Koshki, K., & Baradaran, B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173107 · Cited by 104 · see citing works

Antisense drug discovery and development technology considered in a pharmacological context

Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 104 · see citing works

Targeting STAT3 signaling in kidney disease

Pace, J. A., Paladugu, P., Das, B. C., He, C., & Mallipattu, S. K. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00034.2019 · Cited by 104 · see citing works

STAT3: Versatile Functions in Non-Small Cell Lung Cancer

Mohrherr, J., Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · Cancers · doi:10.3390/cancers12051107 · Cited by 106 · see citing works

Antisense oligonucleotide treatment ameliorates IFN-γ–induced proteinuria in APOL1-transgenic mice

Aghajan, M., Booten, S. L., Althage, M., Hart, C. E., Ericsson, A., Maxvall, I., Ochaba, J., Menschik-Lundin, A., Hartleib, J., Kuntz, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126124 · Cited by 102 · see citing works

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Qiu, P., Zhou, Y., Oyang, L., Wu, N., Tang, Y., Su, M., Luo, X., Wang, Y., Sheng, X., Ma, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.010 · Cited by 103 · see citing works

Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines

Linnane, E., Davey, P. R. J., Zhang, P., Puri, S., Edbrooke, M. R., Chiarparin, E., Revenko, A. S., MacLeod, A. R., Norman, J. C., & Ross, S. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz214 · Cited by 101 · see citing works

MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression

Chang, K.-C., Diermeier, S. D., Yu, A. T., Brine, L., Russo, S., Bhatia, S., Alsudani, H., Kostroff, K. M., Bhuiya, T. A., Brogi, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20207-y · Cited by 96 · see citing works

The revival of CpG oligonucleotide-based cancer immunotherapies

Adamus, T., & Kortylewski, M. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73887 · Cited by 98 · see citing works

RNA-based therapies: A cog in the wheel of lung cancer defense

Κhan, P., Siddiqui, J. A., Lakshmanan, I., Ganti, A. K., Salgia, R., Jain, M., Batra, S. K., & Nasser, M. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01338-2 · Cited by 100 · see citing works

Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics

Scharner, J., & Aznarez, I. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.022 · Cited by 96 · see citing works

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

Shastri, A., Choudhary, G. S., Teixeira, M., Gordon-Mitchell, S., Ramachandra, N., Bernard, L., Bhattacharyya, S., Lopez, R., Pradhan, K., Giricz, O., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120156 · Cited by 94 · see citing works

Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity

Wang, X., Hu, R., Song, Z., Zhao, H., Pan, Z., Feng, Y., Yu, Y., Han, Q., & Zhang, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215880 · Cited by 92 · see citing works

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer

Revenko, A. S., Carnevalli, L. S., Sinclair, C., Johnson, B., Peter, A., Taylor, M. A., Hettrick, L. A., Chapman, M., Klein, S., Solanki, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003892 · Cited by 89 · see citing works

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice

Bitsch, R., Kurzay, A., Kurt, F. G. Ö., Torre, C. D. L., Lasser, S., Lepper, A., Siebenmorgen, A., Müller, V. A., Altevogt, P., Utikal, J. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004384 · Cited by 88 · see citing works

Myeloid cell–targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell–mediated immunity

Moreira, D., Sampath, S., Won, H., White, S. V., Su, Y., Alcantara, M. B., Wang, C., Lee, P. P., Maghami, E. G., Massarelli, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137001 · Cited by 87 · see citing works

Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells.

Huang, T., Guan, X., & Fu, L. (2019) · Europe PMC (PubMed Central) · Cited by 85 · see citing works

Radio Signals from Live Cells: The Coming of Age of In-Cell Solution NMR

Luchinat, E., Cremonini, M., & Banci, L. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00790 · Cited by 86 · see citing works

The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non–small-cell Lung Cancer Through Altering STAT3 Expression

Sun, C., Li, S., Zhang, F., Zhang, Y., Zuo, Z., Xi, Y., Wang, L., & Li, D. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.96 · Cited by 84 · see citing works

Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells

Adamus, T., Hung, C.-Y., Yu, C., Kang, E. Y., Hammad, M., Flores, L., Nechaev, S., Zhang, Q., Gonzaga, J. M., Muthaiyah, K., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.029 · Cited by 84 · see citing works

Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1

Song, S., Su, Z., Xu, H., Niu, M., Chen, X., Min, H., Zhang, B., Sun, G., Xie, S., Wang, H., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.38 · Cited by 83 · see citing works

Engineering Gene Therapy: Advances and Barriers

Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 84 · see citing works

Abstract LB-227: Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3

Hong, D. S., Kim, Y., Younes, A., Nemunaitis, J. J., Fowler, N. H., Hsu, J., Zhou, T., Fayad, L., Zhang, N., Piha-Paul, S. A., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-lb-227 · Cited by 5 · see citing works

Abstract LB-317: Potent in vivo pharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models.

Kim, Y., Hsu, J., Zhou, T., Zhang, N., Woessner, R. D., Nadella, M. V. P., Lawson, D., Reimer, C., He, G., Schmidt, J., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-317 · Cited by 2 · see citing works

Blocking transcription in tumors, STAT

Nusinovich, Y. A. (2015) · Science Signaling · doi:10.1126/scisignal.aad9035

Strong pharmacological activity of locally administered next-generation antisense oligonucleotides (ASOs) in orthotopic lung cancer mouse models

Jo, M., Schmidt, J., Zhou, T., Wu, X., Crosby, J. R., Brand, E., Kim, Y., & MacLeod, A. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.043 · Cited by 1 · see citing works

Abstract C136: Exploring the functional contribution of STAT3 activity in tumor and tumor-associated stromal cells with species-selective generation 2.5 antisense oligonucleotides in preclinical cancer models.

Hsu, J., He, G., Bhattacharjee, G., Zhou, T., Kim, Y., Monia, B. P., & MacLeod, R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c136